pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Immunology · news · pharmadog
← back to Immunology
News mentioning Immunology
280
stories
1d
STAT+: Up and down the ladder: The latest comings and goings
stat
1d
As part of sales reorganization, Novo will cut 215 employees at US HQ
biospace
2d
Regeneron racks up another first as FDA greenlights generalized myasthenia gravis RNA drug
biospace
2d
With FDA nod, Regeneron brings an RNAi drug to autoimmune disease
biopharma dive
3d
Vaccine biotech Evaxion halts infectious disease, autoimmune work to focus on oncology
fiercebiotech
3d
Pfizer leaps into ‘in vivo’ CAR-T with latest China deal
biopharma dive
3d
Pfizer launches into autoimmune CAR T with China's Starna in up to $2.6B deal
biospace
4d
Pfizer enters in vivo CAR-T space via 3-program, $2.6B deal with China’s Starna
fiercebiotech
4d
At Fierce’s London event, Big Pharmas tell biotechs to ‘be transparent’ to secure deals
fiercebiotech
4d
Isomorphic Labs breaks biotech VC fundraising record with $5B series C
biospace
4d
AI drugmaker Isomorphic restocks with $5B fundraise
biopharma dive
5d
NIH’s infectious disease unit has a new head at last
stat
5d
Isomorphic Labs raises $5B series C months after $2.1B round
fiercebiotech
6d
Deaths, failed trials and other recent setbacks in the autoimmune space
biospace
8d
George Church quits AI startup; Ira Mellman’s immunotherapy fight; and more
endpoints
8d
Argenx is spending billions to push beyond Vyvgart
endpoints
9d
Sanofi-backed Windward hits $225M IPO goal, as Rezera delays listing over ‘market conditions’
fiercebiotech
9d
Sofinnova books biggest-ever $815M fund with an eye toward up-and-coming ‘global leaders’
fiercebiotech
9d
Bristol Myers research chief to depart in ‘evolution’ of company’s structure
biopharma dive
11d
Valo and Montai become one as the Flagship AI-based biotechs tie the knot
fiercebiotech
12d
London biotech Oyster harvests $60M for tau-targeting brain drugs
biopharma dive
12d
BioSpace 2027 Best Places to Work shines light on most admired employers
biospace
12d
Argenx to buy peptide platform in potentially billion-dollar deal
biopharma dive
12d
J&J and Protagonist’s Icotyde improves psoriatic arthritis but AbbVie’s Skyrizi likely to reign
biospace
12d
Argenx buyout of peptide engine and Big Pharma favorite UNP could top $1B
biospace
12d
Novo’s troubled cardio drug could find niche in less sick patients
biospace
13d
Sanofi-backed Windward breezes toward $204M IPO to fund respiratory pipeline from China
fiercebiotech
15d
New evidence for ancient cannabis use
stat
16d
Ballot measures affirm divisions over abortion and transgender issues
stat
16d
T-time: British biotech pours $133M into the pot for bispecifics
biospace
← prev
page 1 of 10
next →